kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant human Fms-like tyrosine kinase 3 (FLT3), protein kinase domain, 10 µg  

Recombinant human Fms-like tyrosine kinase 3 (FLT3), protein kinase domain, 10 µg

Recombinant human FLT3 (FMS-like tyrosine kinase 3), protein kinase domain, AS R571-S993) active enzyme

Alternate names: FLT-3, STK1, FLT3, CD135, FLK2, , class III recpetor tyrosine kinase, FMS-like tyrosine kinase 3 protein

More details


Availability: on stock

295,00 €

Background: FLT3 is a tyrosine-protein kinase that belongs to the same family as FMS, KIT and the two genes encoding PDGFRα and β (class III receptor tyrosine kinases) and acts as cell-surface receptor for the cytokine FLT3LG. The downstream signaling cascade involves the tyrosine phosphorylation and activation, Ras GTPase, PLC-γ, Shc, Src family tyrosine kinase affecting the activation of further downstream PI3K/protein kinase B (Akt) and MAPK pathways. FLT3 is normally expressed by hematopoietic stem/progenitor cells (HSPCs) and expression is lost as hematopoietic cells differentiate. In patients with acute myeloid leukemia (AML) FLT3 is frequently mutated either by internal tandem duplications (ITD) of the juxtamembrane domain or by point mutations usually involving the kinase domain (KD).

Protein: human FLT3 (amino acids R571-S993 as in GenBank entry NM_004119), N-terminally fused to GST-HIS6-Thrombin cleavage site

Theoretical MW : 82.1 kDa (fusion proteins)
Expression system: Baculovirus infected Sf9 cells
Purification: One-step affinity purification using glutathione agarose
Storage buffer: 50 mM Tris-HCl, pH 8.0; 100 mM NaCl, 5 mM DTT, 15 mM reduced glutathione, 20% glycerol
Protein concentration: 0.067 mg/ml (Bradford method using BSA as standard protein)
Method for determination of Km value & specific activity: Filter binding assay MAFC membrane
Specific activity: 33.000 pmol/mg x min

Entrez Gene ID: 2322    

Ordering information: shipped on dry ice

Product specific literature:

Small D. (2006) “FLT3 mutations: biology and treatment.” Hematology Am Soc Hematol Educ Program. 2006:178-84.

Small D. (2008) “Targeting FLT3 for the treatment of leukemia.” Semin Hematol. 45(3 Suppl 2):S17-21

Kindler T, Lipka DB, Fischer T. (2010) “FLT3 as a therapeutic target in AML: still challenging after all these years.” Blood. 116(24):5089-102.

Takahashi S. (2011)“Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implications.” J Hematol Oncol. 4:13. doi: 10.1186/1756-8722-4-13.

The following products could also be interesting for you: